Mackay Sean 4
4 · STANDARD BIOTOOLS INC. · Filed Jun 23, 2026
Research Summary
AI-generated summary of this filing
Standard BioTools (LAB) SVP Sean Mackay Receives 500,000 RSU Award
What Happened
- Sean Mackay, SVP & Chief Business Officer of Standard BioTools (LAB), was granted 500,000 restricted stock units (RSUs) on 2026-06-20 (transaction coded as an award/acquisition). The filing reports an acquisition price of $0.00 (no cash paid). Each RSU represents the right to receive one share of common stock upon vesting.
Key Details
- Transaction date: 2026-06-20; SEC filing date: 2026-06-23 (no late filing indicated in the report).
- Award: 500,000 RSUs, reported at $0.00 per unit (code A — award/grant).
- Vesting: 40% (200,000 RSUs) vest on June 20, 2027; remaining 60% (300,000 RSUs) vest on June 20, 2028, subject to continued service (per footnote F1).
- Shares owned after the transaction: not specified in the provided filing summary.
- Footnote: Each RSU converts to one share upon vesting; vesting is service-based.
Context
- RSUs are a form of equity compensation and do not involve an open‑market purchase or immediate share issuance; shares are issued only when RSUs vest. Such awards are commonly used for retention and compensation and should not be read as a direct buy/sell signal.
Insider Transaction Report
Form 4
Mackay Sean
SVP & Chief Business Officer
Transactions
- Award
Common Stock
[F1]2026-06-20+500,000→ 1,506,552 total
Footnotes (1)
- [F1]Represents restricted stock units ("RSUs"), 40% of which will vest on June 20, 2027, and the remaining 60% of which will vest on June 20, 2028 subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Each RSU represents the right to receive one share of common stock upon vesting.
Signature
/s/ Sean Mackay by Tomone Tanaka, Attorney-in-Fact|2026-06-23